Lipocine Inc. (LPCN) Stock Forecast
LPCN analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.00 / 5 from 2 analysts
- Price target
- $5.00 average of analyst targets
- Upside to target
- +220.5% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.39
- 52-week range
- $1.56 – $11.26
LPCN analyst ratings
2 analystsNumber of analysts at each rating.
LPCN price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
LPCN earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.35 | −$0.39 | −$0.32 | −$0.59 | +39.8% | 2 |
| Current fiscal year (2026) | −$1.54 | −$1.55 | −$1.54 | −$1.77 | +12.7% | 2 |
| Next fiscal year (2027) | −$1.34 | −$1.65 | −$1.03 | −$1.54 | +13.3% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
LPCN revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $159,500 | $100,000 | $219,000 | +39.2% | 2 |
| Current fiscal year (2026) | $631,250 | $509,000 | $753,500 | −68.1% | 2 |
| Next fiscal year (2027) | $745,000 | $400,000 | $1.1M | +18.0% | 2 |
LPCN EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
LPCN revenue: reported and forecast
LPCN EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.43 | −$0.43 | −$0.32 | −$0.32 | −$0.35 | −17.4% | 0 up · 0 down |
| Current fiscal year (2026) | −$1.90 | −$1.90 | −$1.55 | −$1.55 | −$1.54 | −18.7% | 0 up · 0 down |
| Next fiscal year (2027) | −$1.65 | −$1.65 | −$1.65 | −$1.65 | −$1.34 | −18.8% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
LPCN earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; LPCN beat in 8 of 12.
What analysts expect from LPCN
2 analysts cover Lipocine; their consensus rating is buy (4.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $5.00, 220.5% above the latest close of $1.56. Analysts expect earnings of −$1.54 per share for 2026, +12.7% from a year earlier. For 2027 the average estimate is −$1.34 per share on revenue of $0.7 million. Lipocine beat the EPS estimate in 8 of the last 12 quarters.
Related: LPCN income statement, LPCN key metrics, LPCN chart. See the LPCN stock overview for the latest quote and news.
LPCN forecast FAQ
What is Lipocine's price target?
The average analyst price target for Lipocine is $5.00, 220.5% above the latest close of $1.56.
Is Lipocine a buy, hold or sell?
Of 2 analysts covering Lipocine, 1 rate it a strong buy, 0 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Lipocine's EPS forecast?
Analysts forecast −$1.54 per share for 2026 (range −$1.55 to −$1.54); for 2027 the estimate is −$1.34.
What is Lipocine's revenue forecast?
The average revenue estimate for 2026 is $0.6 million, growth of −68.1%; for 2027 it is $0.7 million.
When does Lipocine report earnings?
Lipocine is expected to report results for the quarter ending September 30, 2026 on November 5, 2026; the EPS estimate is $-0.39.
Does Lipocine usually beat earnings estimates?
Lipocine reported EPS at or above the analyst estimate in 8 of the last 12 quarters.